Pioglitazone/azilsartan

Drug Profile

Pioglitazone/azilsartan

Alternative Names: Actos/TAK-536; AD 4883 536; Azilsartan/pioglitazone; Pioglitazone/TAK 536; TAK-536/pioglitazone

Latest Information Update: 26 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda Global Research and Development Center
  • Class Antihyperglycaemics; Benzimidazoles; Oxadiazoles; Thiazolidinediones
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 01 Jun 2007 Discontinued - Phase-III for Type-2 diabetes mellitus (associated with hypertension) in USA (PO)
  • 21 Jul 2006 Phase-III clinical trials in Hypertension in USA (PO)
  • 21 Jul 2006 Phase-III clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top